Printer Friendly
The Free Library
14,635,740 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Snow Brand Milk Products Confirms that Cheese Intake Inhibits Visceral Fat Accumulation.


Tokyo, Japan, May 16, 2006 - (JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) 
) - Snow Brand Milk Products announced on May 12 that it has found a unique property of cheese.

In the recent experiments using rats, the company confirmed that an intake of cheese (Gouda cheese) substantially reduces total cholesterol levels and neutral fat in the blood as well as visceral fat Visceral fat, also known as organ fat, is located inside the peritoneal cavity, packed in between internal organs, as opposed to subcutaneous fat which is found underneath the skin and intramuscular fat which is found interspersed in skeletal muscle.  accumulation in the bowels.

In addition, the results indicate that cheese also helps maintain adiponectin production at a certain level. Adiponectin is a kind of index for diagnosing cardiovascular diseases Cardiovascular disease
Disease that affects the heart and blood vessels.

Mentioned in: Lipoproteins Test

cardiovascular disease 
.

Snow Brand Milk Products has concluded that the intake of cheese may prevent metabolic syndrome metabolic syndrome
n.
See syndrome X.


Metabolic syndrome
A group of risk factors for heart disease, diabetes, and stroke.
 and cardiovascular diseases. Details of the research will be presented at the 60th Annual Meeting of the Japanese Society of Nutrition and Food Science to be held in Shizuoka from May 19 to 21.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:May 16, 2006
Words:144
Previous Article:Fujitsu Revamps Its Pharmaceutical Development Solutions.
Next Article:Olympus Medical Systems to Release Endoscopic Video System.



Related Articles
Investigate the microbial safety of process cheeses.
Serum ferritin concentration and fat distribution. (Letters to the Editor).(Letter to the Editor)
Milking the data: does dairy burn more fat? Don't bet your bottom on it.
Study links dairy products to moderate breast cancer risk reduction.(An Advertising Supplement)(Advertisement)
Kobayashi Pharmaceutical Confirms That Eucommia Ulmoies Helps Improve Metabolic Syndrome.
Development of food groupings to guide dietary advice for people with diabetes.
Fujicco to Announce Research Findings of Black Soybean at Academic Conference.
Of interest from the journals.(glycaemic control type II diabetic tube-fed patients )
Body shape changes: where are we?

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles